Reduced incidence of mortality is greatest unmet need in post-myocardial infarction, say US cardiologists and MCOs

According to insights from US cardiologists and managed care organization (MCO) pharmacy directors surveyed by advisory firm Decision Resources, the reduced incidence of mortality is the greatest unmet need in post-myocardial infarction. Xarelto (rivaroxaban) has demonstrated potential to significantly fulfill this unmet need, it was revealed.

“Despite the declining rate of deaths due to myocardial infarction and despite the emergence of novel antiplatelet agents and optimal statin therapy, the incidence of mortality remains the attribute that most influences surveyed cardiologists’ prescribing decisions in post-myocardial infarction,” said Decision Resources analyst Conor Walsh, adding: “According to clinical data and thought leaders we interviewed, Bayer/Janssen’s Xarelto has demonstrated the potential to significantly fulfill this unmet need.”

Clinical data and interviewed thought leaders also indicate that the regimen of aspirin (Bayer’s Aspirin, generics) plus ticagrelor (AstraZeneca’s Brilinta/Brilique) plus atorvastatin (Pfizer’s Lipitor, generics) plus metoprolol (AstraZeneca’s Toprol, Novartis’ Lopressor, generics) plus ramipril (Pfizer’s Altace, Sanofi’s Triatec, AstraZeneca’s Vesdil, generics) has advantages on the attribute of reduced incidence of mortality over the sales-leading regimen for post-myocardial infarction - aspirin plus clopidogrel (Sanofi/Bristol-Myers’ Plavix/Iscover, generics) plus atorvastatin plus metoprolol plus ramipril.